Dosing & Uses
Heart Failure
Pending FDA approval for treatment of heart failure with reduced ejection fraction (HFrEF)
Next:
Pharmacology
Mechanism of Action
First-in-class cardiac myosin activator; improves myocardial function by directly augmenting cardiac sarcomere function
Enhances cardiac contractility by selective binding to and recruiting more cardiac myosin heads to interact with actin during systole; this action increases the number of active actin-myosin cross bridges during each cardiac cycle and consequently augments impaired contractility associated with HFrEF
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
